Characterization of DCs on day 7 under different conditions: quantification of data from 4 donors
DC surface markers . | DC treatment: (4 donors) . | . | . | ||
|---|---|---|---|---|---|
| . | lysate (mock) . | wt AAV . | AAV/HM1.24/Neo . | ||
| CD14 | |||||
| % | 11.8 ± 4 | 12.3 ± 2 | 11.3 ± 2 | ||
| MFI | 148.3 ± 58 | 118.3 ± 41 | 112.0 ± 45 | ||
| CD80 | |||||
| % | 70.0 ± 8 | 77.8 ± 6.6 | 91.0 ± 6 | ||
| MFI | 713.0 ± 195 | 1857.0 ± 165* | 2729.0 ± 751* | ||
| CD86 | |||||
| % | 72.2 ± 5 | 83.0 ± 5 | 86.0 ± 6 | ||
| MFI | 1216.0 ± 275 | 1983.0 ± 87* | 1709.0 ± 127 | ||
| CD40 | |||||
| % | 65.5 ± 6 | 74.5 ± 5 | 81.8 ± 1 | ||
| MFI | 937.0 ± 122 | 1401.0 ± 291 | 1356.0 ± 187 | ||
DC surface markers . | DC treatment: (4 donors) . | . | . | ||
|---|---|---|---|---|---|
| . | lysate (mock) . | wt AAV . | AAV/HM1.24/Neo . | ||
| CD14 | |||||
| % | 11.8 ± 4 | 12.3 ± 2 | 11.3 ± 2 | ||
| MFI | 148.3 ± 58 | 118.3 ± 41 | 112.0 ± 45 | ||
| CD80 | |||||
| % | 70.0 ± 8 | 77.8 ± 6.6 | 91.0 ± 6 | ||
| MFI | 713.0 ± 195 | 1857.0 ± 165* | 2729.0 ± 751* | ||
| CD86 | |||||
| % | 72.2 ± 5 | 83.0 ± 5 | 86.0 ± 6 | ||
| MFI | 1216.0 ± 275 | 1983.0 ± 87* | 1709.0 ± 127 | ||
| CD40 | |||||
| % | 65.5 ± 6 | 74.5 ± 5 | 81.8 ± 1 | ||
| MFI | 937.0 ± 122 | 1401.0 ± 291 | 1356.0 ± 187 | ||
Monocytes from 4 donors were generated by the 3 loading techniques and were stimulated to differentiate into DCs by GM-CSF and IL-4, as indicated in “Materials and Methods” and shown in Figure 2. Values shown indicate mean ± SD. Three DC populations were analyzed using FACS for MFI and percentage of positivity. For the analysis of DCs, a panel of mAbs recognizing the following antigens was used: anti-CD40 (Immunotech, Marseilles, France), anti-CD14, anti-CD80 (BD Biosciences), and anti-CD86 (BD Biosciences-PharMingen, San Diego, CA). Data represent 4 independent experiments performed in quadruplicate.
MFI indicates mean fluorescence intensity.
% indicates percentage of positivity.
indicates the largest difference from the lysate control.